Klin Farmakol Farm. 2010;24(3):145-151

Teratogenity of drugs and its importance for rational pharmacotherapy

Jana Schwarzová1, Mária Belovičová2, Martin Wawruch3
1 Študentka 4. ročníka Fakulty medicíny Slovenskej zdravotníckej univerzity, Bratislava
2 Ústav farmakológie a klinickej farmakológie Slovenskej zdravotníckej univerzity, Národné referenčné centrum pre liečbu chronických hepatitíd, Bratislava
3 Ústav farmakológie a klinickej farmakológie Lekárskej fakulty Univerzity Komenského, Bratislava

The knowledge on the importance of drugs´ teratogenity plays a significant role in the process of rational pharmacotherapy. Women

represent almost half of adult patients and a part of them is in fertile period when the potential teratogenity risk should be considered.

The drugs could be administered for a long time or for a short term treatment of acute conditions. The teratogenic effect of a drug

depends on: the period of pregnancy in time when the drug is applied, the duration of drug administration, genotype of mother and

foetus, dosage of active substance which is effecting on foetus. It is estimated that drugs contribute to development up to 5 % of all foetal

anatomic abnormalities. Teratogenic agents may cause barely observable abnormalities of biochemical and physiologic processes as

well as changes in behaviour, however the dosages of teratogens are much more less than those causing anatomic abnormalities. Many

of these latent abnormalities are not observed after birth and they are revealed many years later. The most important factor which plays

an important role in doctor’s decision making process before administration of a drug is the consideration of benefit of treatment of

disease of mother, evaluation whether the mother’s disease may cause teratogenic effect and whether mother’s recovery may lead to

improvement of health status of foetus. The authors list the examples of teratogenic effects of concrete drugs during pregnancy.

Keywords: teratogenity of drugs, teratogen, placenta, pregnancy

Published: October 15, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Schwarzová J, Belovičová M, Wawruch M. Teratogenity of drugs and its importance for rational pharmacotherapy. Klin Farmakol Farm. 2010;24(3):145-151.
Download citation

References

  1. Summer JY, Gerald GB, Pharm B. Rizika podávní léčiv v těhotenství. Gynekologie po promoci 2004; 4: 35-40.
  2. Kriška M, Božeková L, Sirotiaková J. Lieky a gravidita. In: Kriška M, a kol. Memorix klinickej farmakológie a liekov. 1 vyd. Bratislava: SAP, 2006: 103-111.
  3. Schardein JL. Chemically Induced Birth Defects. 3. vyd. New York, NY: Marcel Dekker, Inc.; 2000. Go to original source...
  4. Shepard TH. Dose Response in Human Teratology. Teratology 2002; 65: 199-200. Go to original source... Go to PubMed...
  5. Schaeffer CH (ed). Drugs During Pregnancy and Lactation. Amsterdam, Elselvier, 2001: 368.
  6. Jeseňák M, Lietavová Z, Szokeová A, Lietava P, Plameňová I, Mráz M, Babušíková E, Buchanec J, Bánovčin P. Thalidomid -, ,novodobý comeback". Klin Farmakol Farm 2007; 21(3-4): 128-132.
  7. www.sukl.sk 24.01.2010.
  8. Elis J, Elisová K. Léky v těhotenství. Praha. Avicenum, 1989: 208.
  9. Perlík F. Klinická farmakologie v praxi. Praha. Triton, 1999: 149.
  10. Santis M, Straface G, Cavaliere AF, Carducci B, Caruso A. Gadolinium periconceptional exposure: pregnancy and neonatal outcome. Acta Obstetrica et Gynecologica. 2007; 86: 99-100. Go to original source... Go to PubMed...
  11. Cuzzell J. Paroxetine May Increase Risk for Congenital Malformations. Dermatology Nursing. 2006; 18: 68.
  12. Briggs G, Freeman RK, Yaffe SJ. (eds.): Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk, 7th ed., Philadelphia, Lippincot Williams Wilkins, 2005; 2047p.
  13. Kristová V, Wawruch M. Použitie vybraných psychofarmák počas gravidity. In: Pokroky v biomedicíne 2007. Bratislava: Slovenská biologická spoločnosť pri SAV, 2007; 86-89.
  14. AISLP, 2005.
  15. Einarson A. The safety of psychotropic drug use during pregnancy: A review. Medscape General Medicine 2005; 7(4): 1-9.
  16. Fedelešová V. Liečba hypertenzie v tehotenstve. Via practica 2004; 3: 151-154.
  17. Výbor pre odporúčania: Odporúčania Európskej hypertenziologickej spoločnosti a Európskej kardiologickej spoločnosti pre rok 2003 v manažmente artériovej hypertenzie pre rok 2003. Cardiol 2004; 13(1): 33-72.
  18. Rey E. Effect of methyldopa on umbilical and placental artery blood flow velocity wavsforms. Obst gynecol 1992; 80: 783-787.
  19. Lip GY. Effect of atenolol on birthweight. Am J Cardiol 1997; 79: 1436-1438. Go to original source... Go to PubMed...
  20. Papatsonis DN, Lok CA, Bos JM, Geijn HP, Dekker GA. Calcium chanel blokers in management of preterm labor and hypertension in pregnancy. Eu J Obstet Gynecol Reprod Biol. 2001; 97: 122-140. Go to original source... Go to PubMed...
  21. Reif MC. Symptom severity and timing of onset determine clinical action. Women Heath Primery care 2003; 6: 194-200.
  22. Tabacova S. Angiotensin-Converting Enzyme Inhibition - Developmental Effects Associated With Exposure to ACE Inhibitors. Critical Reviews in Toxicology. 2005; 35: 747-755. Go to original source... Go to PubMed...
  23. Hrubiško M. Bronchiálna astma a gravidita. www.alergo.sk 24.01.2010.
  24. Coussins L. Fetal oxygenation, assessment of fetal wellbeing, and obstetric management of the pregnant patient with asthma. J Allergy Clin Immunol. 1999; 103: 343-349. Go to original source... Go to PubMed...
  25. Alexander S, Dodds L, Armson BA. Perinatal outcomes in women with asthma during pregnancy. Obstet Gynecol. 1998; 92: 435-440. Go to original source... Go to PubMed...
  26. Kristová V, Wawruch M. Uplatnenie H1-antihistaminík v liečbe alergických ochorení. Pokroky v biomedicíne 2007. Slovenská biologická spoločnosť pri SAV 2007: 90-93.
  27. Horak F, Stubner PU. Comparative tolerability of second generation antihistamines. Drug safety 1999; 20: 385-401. Go to original source... Go to PubMed...
  28. Grey E, Trizuljaková P, Kačmariková M. Antibiotiká, chemoterapeutiká a ich podávanie v tehotenstve. Via practica. 2004; 2: 221-223.
  29. Bossens M. Antibiotiques et grossesse. Revue medicale de Beuxelles, 2001; 22(4), pp. A206-A203.
  30. Vaules MB, Ramin KD, Ramsey PS. Syphilis in pregnancy: a review. Primary care update for OB/GYNS, Volume 7, Issue 1, 2000: pp. 26-30. Go to original source...
  31. Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A teratological study of aminoglycoside antibiotic treatment during pregnancy. Scandinavian journal of infectious diseases 2000; 32(3): 309-313. Go to original source... Go to PubMed...
  32. Ács N, Bánhidy F, Puhó E, Czeizel A. Population-based case-control study of mebendazol in pregnant woman for birth outcomes. Congenital Anomalies. 2005; 45: 85-88. Go to original source... Go to PubMed...
  33. Kriška M, Kristová V, Sirotiaková J, Rybár I, Rovenský J. Farmakoterapia nesteroidnými antiflogistikami v gravidite a laktácii. Praktická gynekológia. 1998; 2: 45-53.
  34. Rumack CM, Guggenheim MA, Rumack BH, et al. Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet. Gynecol., 1981; 58(Suppl) 52S-56S.
  35. Wiggins DA, Elliot JP. Oligohydramnions in each sac of a triplet gestation caused by Motrin-fulfilling Koc. s postulates. Am. J. Obstet. Gynecol., 1990; 162: 460-461. Go to original source... Go to PubMed...
  36. Netter JC, Choulot JJ, Dagues-Bie M, et al. Oligohydramnios and persistent pulmonary arterial hypertension after use of ketoprofen during pregnancy. Sem. Hop. Paris, 66, 1990: 1953-1954.
  37. Morales WJ, Madhav H. Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. Am. J. Obstet. Gynecol., 1993; 196: 97-102. Go to original source... Go to PubMed...
  38. Abadi S, Einarson A, Koren G. Use of warfarin during pregnancy. Canadian Family Physician. 2002; 48: 695-697. Go to PubMed...
  39. Whitfield MF. Chondroplasia punctata after warfarin in early pregnancy. Archives of Diseases in Childhood. 1980; 55: 139-142. Go to original source... Go to PubMed...
  40. Kelly E. Fitzgerald. Use of Phenytoin in Pregnancy for Epileptic Seizure Prevention: A Case Report. Journal of Midwifery & Women's Health. 2004; 49: 145-147. Go to original source... Go to PubMed...
  41. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93: 174-176. Go to original source... Go to PubMed...
  42. Adab N, Chadwick DW. Management of women with epilepsy during pregnancy. The Obstetrician & Gynaecologist 2006; 8: 20-25. Go to original source...
  43. www.teratology.org/jfs/Pharmaceutical.html 23.12.2009.
  44. Dudas I, Glidai J, Czeizel E. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenital Anomalies. 2006; 46: 194-198. Go to original source... Go to PubMed...
  45. Šteňová Emoke, Koreň Michal. Systémová kortikoterapia - špecifiká liečby glukokortikoidmi. Ambulantná terapia 2009; 7(1): 38-42.
  46. Wilson Douglas R, et al. Principles of Human Teratology: Drug, Chemical, and Infectious Exposure. JOGC. 2007; 911-917. Go to original source... Go to PubMed...
  47. Jeanty P, Silva S. VACTERL Association. www.thefetus.net/ page.php? id=446 20.12.2009.
  48. Källén Bengt AJ. Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenital Anomalies 2005; 45: 44-51. Go to original source... Go to PubMed...
  49. Koren G. Mycophenolate mofetil. Emerging as a potential human teratogen. Canadian Family Physician. 2008; 54: 1112-1113. Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.